Aorta Company Limited Pharmaceutical Import Profile — Myanmar (DGFT 2022–2026)

Name: Aorta Company Limited Pharmaceutical Import Records from India — 2 Products, $4.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Aorta Company Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $4.0M Trade | TransData Nexus

Aorta Company Limited

Pharmaceutical Importer · Myanmar · Antibiotics Focus · $4.0M Total Trade · DGFT Verified

Aorta Company Limited is a pharmaceutical importer based in Myanmar with a total trade value of $4.0M across 2 products in 2 therapeutic categories. Based on 88 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Aorta Company Limited sources from 5 verified Indian suppliers, with Amn Life Science Private Limited accounting for 64.5% of imports.

Aorta Company Limited — Import Portfolio & Supplier Network

Aorta Company Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Aorta Company Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Amn Life Science Private Limited	$14.6M	659	64.5%
Amn Life Private Limited	$6.9M	293	30.6%
Beta Drugs Limited	$983.7K

What Formulations Does Aorta Company Limited Import?

Formulation	Value	Ships
Amnacloxa(ampicillin and cloxacillin	$1.1M	26
Moxitam 250(amoxicillin capsule BP 250MG	$389.0K	12
Medicine for human consumption	$356.3K	17
Medicine for human consumption amcort	$323.8K	17
Avam 625 amoxicillin and clavulanate	$313.2K	11
Betacef 500(cefalexin capsules BP 500 MG	$289.1K	8
Medicine for human consumption	$270.9K	13
Moxitam 250 amoxicillin capsule BP	$250.0K	5
Moxitam 500(amoxicillin 500MG capsule	$247.7K	8
Medicine for human consumption	$205.4K	7
Amnacloxa (ampicillin and cloxacillin	$200.0K	4
Moxitam 500 (amoxicillin 500MG capsule)	$200.0K	4
Pharmaceutical go article / ods / product / item moxitam	$176.1K	8
Medicine for human consumption amentro	$175.4K	13
Medicine for human consumption moxitam	$158.4K	15

Aorta Company Limited imports 668 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ampicillin	Antibiotics	$3.7M	74	2.6%	3
2	Ranitidine	Gastrointestinal	$336.8K	14	2.7%	6

Aorta Company Limited imports 2 pharmaceutical products across 2 categories into Myanmar totaling $4.0M.

Aorta Company Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Aorta Company Limited is a pharmaceutical importer based in Myanmar, specializing in the procurement of finished pharmaceutical formulations from India. The company operates as a buyer, sourcing a diverse range of pharmaceutical products to meet the healthcare needs within Myanmar. While specific details about its headquarters and parent company are not publicly disclosed, Aorta Company Limited plays a significant role in the distribution of imported pharmaceutical products across the country.

2Distribution Network

Information regarding Aorta Company Limited's warehouse locations and logistics capabilities is not publicly available. However, given its substantial import activities, it is likely that the company has established a distribution network within Myanmar to effectively manage the delivery of pharmaceutical products. The extent of its geographic coverage beyond Myanmar remains unspecified.

3Industry Role

Aorta Company Limited functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from Indian suppliers. Its role in Myanmar's pharmaceutical supply chain involves facilitating the availability of imported medications, thereby contributing to the country's healthcare sector. The company's specific position—whether as a wholesaler, parallel importer, hospital supplier, or logistics intermediary—cannot be conclusively determined based on the available data.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Aorta Company Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Aorta Company Limited demonstrates a high degree of sourcing concentration, with its top five products accounting for 100% of its imports. This indicates a strategic focus on a limited product range, which may streamline operations but also exposes the company to risks associated with supply chain disruptions or changes in market demand for these specific products. The substantial import values and consistent shipment volumes suggest a stable and ongoing relationship with its Indian suppliers, particularly with AMN Life Science Private Limited and AMN Life Private Limited, which together account for 95.1% of the total import value.

2Supply Chain Resilience

The resilience of Aorta Company Limited's supply chain appears to be robust, given the consistent import volumes and the dominance of a few key suppliers. However, the lack of publicly available information on backup suppliers and the diversity of formulations imported makes it challenging to fully assess the company's preparedness for potential supply chain disruptions. The company's reliance on a limited number of suppliers may pose risks if any of these suppliers face operational challenges or regulatory issues.

3Strategic Implications

Importing Pharmaceuticals into Myanmar — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Myanmar

1Regulatory Authority & Framework

The Food and Drug Administration (FDA) of Myanmar is the primary regulatory body overseeing the importation, registration, and distribution of pharmaceutical products in the country. The National Drug Law (Law No. 7/1992), enacted on October 30, 1992, serves as the foundational legislation governing these activities. This law outlines the procedures for drug registration, licensing, quality assurance, labeling, and advertising, aiming to ensure the safety, efficacy, and quality of pharmaceutical products in Myanmar. (wipo.int)

2Import Licensing & GMP

To import pharmaceutical products into Myanmar, companies must obtain an Import License from the FDA. This license is contingent upon the submission of comprehensive documentation, including Certificates of Pharmaceutical Product (CPP) from the exporting country, which attest to the compliance of the products with international quality standards. Additionally, the FDA requires that imported drugs adhere to Good Manufacturing Practice (GMP) standards recognized by international bodies such as the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

3Quality & Labeling

Aorta Company Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Aorta Company Limited's focus on importing antibiotics and gastrointestinal medications suggests a strategic alignment with prevalent health concerns in Myanmar, where infectious diseases and gastrointestinal disorders are common. The substantial import value of ampicillin indicates a significant demand for antibiotics, while the inclusion of ranitidine reflects a need for treatments addressing stomach acid-related issues. This product strategy is likely driven by market demand and the company's objective to meet the therapeutic needs of the population.

2Sourcing Profile

Aorta Company Limited's sourcing strategy is centered on generic pharmaceutical formulations, primarily from India. The company's preference for finished formulations over raw Active Pharmaceutical Ingredients (APIs) suggests a focus on ready-to-market products, which can expedite distribution and reduce operational complexities. India's established pharmaceutical manufacturing capabilities and competitive pricing make it an attractive sourcing destination for Aorta Company Limited.

3Market Positioning

Based on its product mix, Aorta Company Limited serves the wholesale distribution segment of the Myanmar pharmaceutical market. By importing a range of antibiotics and gastrointestinal medications, the company likely supplies these products to various healthcare providers, including hospitals, clinics, and pharmacies, thereby contributing to the broader healthcare infrastructure in Myanmar.

Seller's Guide — How to Become a Supplier to Aorta Company Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Aorta Company Limited, particularly those offering high-quality generic formulations that align with the company's current product focus. Expanding the product range to include additional therapeutic areas could also present growth opportunities. However, potential suppliers should be prepared to navigate Myanmar's regulatory landscape and ensure compliance with the FDA's requirements to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply Aorta Company Limited must ensure that their products are registered with the FDA of Myanmar and comply with the GMP standards recognized by international bodies such as WHO and PIC/S. Additionally, products must meet the labeling requirements set forth by the FDA, including information in the Burmese language. Obtaining the necessary import licenses and adhering to quality assurance protocols are essential steps in the process.

3How to Approach

Frequently Asked Questions — Aorta Company Limited

What products does Aorta Company Limited import from India?

Aorta Company Limited imports 2 pharmaceutical products across 2 categories. Top imports: Ampicillin ($3.7M), Ranitidine ($336.8K).

Who supplies pharmaceuticals to Aorta Company Limited from India?

Aorta Company Limited sources from 5 verified Indian suppliers. The primary supplier is Amn Life Science Private Limited (64.5% of imports, $14.6M).

What is Aorta Company Limited's total pharmaceutical import value?

Aorta Company Limited's total pharmaceutical import value from India is $4.0M, based on 88 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Aorta Company Limited focus on?

Aorta Company Limited imports across 2 categories. The largest: Antibiotics (91.7%), Gastrointestinal (8.3%).

Get Full Aorta Company Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.